WebDisclosure WebDisclosure
Basculer en Français
10097 Companies
206657 Keywords
136824 Articles
109538 Press releases
Headlines Articles Press releases Applied DNA Sciences, Inc. Remove
  1. Home
  2. Companies
  3. Applied DNA Sciences, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • PRESS RELEASE

    published on 08/07/2023 at 17:00, 2 years 7 months ago

    Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023

    Logo of Applied DNA Sciences, Inc.
  • PRESS RELEASE

    published on 07/18/2023 at 16:00, 2 years 8 months ago

    Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences

    Logo of Applied DNA Sciences, Inc.
  • PRESS RELEASE

    published on 07/13/2023 at 13:15, 2 years 8 months ago

    Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach

    Logo of Applied DNA Sciences, Inc.
  • PRESS RELEASE

    published on 06/08/2023 at 17:00, 2 years 9 months ago

    Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference

    Logo of Applied DNA Sciences, Inc.
  • PRESS RELEASE

    published on 05/11/2023 at 22:05, 2 years 10 months ago

    Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update

    Logo of Applied DNA Sciences, Inc.
Previous page
1 ... 9 10
Accesswire
  • Published on 03/26/2026 at 08:05, 2 hours 54 minutes ago

    Vanta Announces U.S. Ticker Symbol Change to VNTXF

  • Published on 03/26/2026 at 04:55, 6 hours 4 minutes ago

    Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives

  • Published on 03/26/2026 at 00:40, 10 hours 19 minutes ago

    Challenger RC Resource Upgrade Drilling Complete

  • Published on 03/26/2026 at 00:30, 10 hours 29 minutes ago

    Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results

  • Published on 03/25/2026 at 19:15, 15 hours 44 minutes ago

    Gemina Laboratories Ltd. Announces Delisting from the CSE

View all ACCESSWIRE
EQS Group
  • Published on 03/26/2026 at 10:45, 14 minutes ago

    Nonstop in 11 Hours to the 'City of Pandas': Chengdu Launches Direct Flights to Brussels

  • Published on 03/26/2026 at 10:30, 28 minutes ago

    Cando Solar introduces solar wing solution "Cando Solar Cloth," making scalable and lightweight solar power a reality

  • Published on 03/26/2026 at 10:05, 53 minutes ago

    Holding(s) in Company

  • Published on 03/26/2026 at 10:05, 53 minutes ago

    'SOMEBODY TOLD ME' THE KILLERS ARE HEADLINING THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®

  • Published on 03/26/2026 at 10:00, 58 minutes ago

    No Limits, Just Beginnings: NAVEE Enters a New Performance Era in Germany

View all EQS
Les Echos
  • Published on 03/26/2026 at 08:57, 2 hours 1 minute ago

    Communiqué Edenred

  • Published on 03/26/2026 at 08:57, 2 hours 1 minute ago

    Edenred statement

  • Published on 03/26/2026 at 07:30, 3 hours 29 minutes ago

    BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY

  • Published on 03/26/2026 at 07:30, 3 hours 29 minutes ago

    BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ

  • Published on 03/25/2026 at 18:53, 16 hours 5 minutes ago

    CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy